GOSSELIES, Belgium I April 24, 2025 I Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of ...

Session: Rapid Oral Abstract Sessions: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology ...

Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic platform against a range of cancer indications, emerged from stealth today with ...

First-in-class ERG degrader is designed to treat the 40-50% of prostate cancers displaying ERG-TMPRSS2 fusions - ...

ALAMEDA, CA, USA and TAIPEI, Taiwan I April 21, 2025 I Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its ...

MARSEILLE, France I April 22, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January ...

WASHINGTON, DC, USA I April 16, 2025 I The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine candidate, administering doses to the first ...

MELBOURNE, Australia and INDIANAPOLIS, IN, USA I April 16, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 ...

First-in-human trial of ETX–636 to begin in Q2 2025 in patients with tumors harboring an activating PI3Kα mutation, including breast cancer ...

BOSTON, MA, USA I April 15, 2025 I Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today announced that ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...

Cryopreserved allogeneic Treg infusions associated with slowed disease progression and decreased plasma neurofilament level in ALS ...